Overview
- Casgevy, the first approved CRISPR-based therapy, gained clearance for sickle cell disease in late 2023 and for beta thalassemia in early 2024.
- Vertex now says full-year 2025 revenue for the product could exceed $100 million.
- Under their agreement, Vertex keeps 60% of Casgevy profit and CRISPR Therapeutics receives 40%, curbing CRISPR Therapeutics’ near-term earnings.
- Commercialization depends on authorized treatment centers and a multi-month process of cell collection, gene editing, and reinfusion, limiting throughput.
- Despite some recovery this year, CRISPR Therapeutics’ stock remains more than 60% below its 2021 peak.